(Las Vegas, Nevada, United States) – September 10, 2026: DelveInsight’s “Eosinophilic Esophagitis Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Eosinophilic Esophagitis, historical and forecasted epidemiology as well as the Eosinophilic Esophagitis market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Get a Free sample for the Eosinophilic Esophagitis Market Report:
https://www.delveinsight.com/report-store/eosinophilic-esophagitis-market
Some of the key facts of the Eosinophilic Esophagitis Market Report:
The Eosinophilic Esophagitis market size was valued at approximately USD 901 million in 2025 and is projected to reach nearly USD 3,543 million by 2036, expanding at a robust CAGR of 12.9% during the study period from 2022 to 2036.
The Eosinophilic Esophagitis market in the United States was valued at approximately USD 650 million in 2025 and is projected to reach around USD 2,800 million by 2036, growing at a CAGR of 14% during the forecast period from 2026 to 2036.
In June 2026, preclinical contract research organization HKeyBio launched HKEY-ExE 1.0, an innovative evaluation framework tailored for eosinophilic esophagitis (EoE) and eosinophilic gastroenteritis (EgE). Designed to address persistent bottlenecks in preclinical drug development, the platform integrates automated disease modeling, multi-dimensional efficacy endpoint assessment, and biomarker analysis for type 2 inflammation. This comprehensive tool allows global drug developers to precisely validate therapeutic mechanisms, evaluate tissue remodeling, and streamline cross-indication translational research across multiple complex gastrointestinal sites.
In June 2026, Phathom Pharmaceuticals completed patient enrollment ahead of schedule for its Phase 2 pHalcon-EoE-201 clinical trial. The randomized, placebo-controlled study is actively evaluating VOQUEZNA (vonoprazan) tablets as an investigational, non-steroidal oral treatment for adults with eosinophilic esophagitis (EoE). By assessing targeted acid suppression therapy over a 12-week period, the trial aims to establish whether vonoprazan can effectively reduce tissue inflammation and dysphagia symptoms, potentially broadening the available landscape of oral EoE treatments.
In May 2026, Sanofi and Regeneron announced positive results from the REMODEL Phase 4 trial evaluating Dupixent (dupilumab) in adults with eosinophilic esophagitis (EoE) at DDW 2026. The study demonstrated that Dupixent significantly improved esophageal distensibility, a key measure of organ function, while reversing disease-related structural damage and underlying tissue inflammation over 24 weeks. These clinical findings highlight Dupixent’s potential to modify EoE’s progressive course, offering patients an effective therapeutic alternative to invasive esophageal dilation procedures.
In May 2026, Takeda Pharmaceuticals expanded its gastrointestinal advocacy portfolio by launching the “Finding the Words” campaign to illuminate the challenging diagnostic journey of eosinophilic esophagitis (EoE). Featuring real-world patient testimonials, the initiative highlights how common symptoms like dysphagia and subtle adaptive eating behaviors frequently mask the progressive condition, delaying crucial clinical intervention. By updating its global newsroom with these educational resources, Takeda aims to improve public understanding, accelerate early diagnosis, and support families navigating this complex chronic illness.
In May 2026, Sanofi Medical updated its scientific congress platform to showcase extensive clinical data presented at Digestive Disease Week (DDW) 2026. The clinical updates focused heavily on microscopic outcomes from the Phase 4 REMODEL study, showing that Dupixent achieved a 59% histologic remission rate in EoE patients compared to just 4% for placebo. By offering healthcare professionals direct access to these deep cellular, grade, and stage scoring metrics, Sanofi aims to reinforce the critical role of IL-4 and IL-13 inhibition in halting gastrointestinal tissue remodeling.
In January 2026, Phantom Pharmaceuticals anticipates topline data in 2027 from its Phase II clinical trial (pHalcon-EoE-201) in patients with EoE.
In 2025, the United States held the largest market share for EoE among the 7MM, accounting for approximately 72% of the total market.
In 2025, DUPIXENT led the US EoE treatment market and is projected to retain its position as the dominant market leader through 2036.
In 2025, Proton Pump Inhibitor (PPIs) treatment for EoE generated approximately USD 346 million in revenue across the 7MM countries.
In the 7MM, the US accounted for the highest diagnosed prevalent cases of eosinophilic esophagitis in 2025, with around 512,000 cases; these numbers are expected to increase during the forecast period.
Eosinophilic Esophagitis predominantly affected males, with approximately 332,000 males diagnosed compared to 179,000 females in 2025 in the US.
In the EU4 and the UK, individuals over the age of 18 were the most affected by Eosinophilic Esophagitis, with approximately 395,000 cases reported in 2025.
Key Eosinophilic Esophagitis Companies: Sanofi/Regeneron Pharmaceuticals, Dr. Falk Pharma GmbH, AstraZeneca and Amgen, Ellodi Pharmaceuticals, Aquestive Therapeutics, Atnahs Pharma (Pharmanovia), Jazz Pharmaceuticals, SK Biopharmaceutical, Angelini Pharma/Ono Pharmaceutical, Novartis, Xenon Pharmaceuticals, Takeda, Ovid Therapeutics, Biohaven Pharmaceuticals/Knopp Biosciences, and others
Key Eosinophilic Esophagitis Therapies: Dupilumab (DUPIXENT), Budesonide (JORVEZA), Tezepelumab (TEZSPIRE), APT-1011 (fluticasone propionate), LIBERVANT (diazepam buccal film), EPIDIOLEX/EPIDYOLEX (cannabidiol), XCOPRI/ONTOZRY (cenobamate), AFINITOR DISPERZ/VOTUBIA (everolimus), XEN1101/Azetukalner, Soticlestat (TAK-935), BHV-7000 (KB-3061), and others
The Eosinophilic Esophagitis epidemiology based on gender analyzed that Eosinophilic Esophagitis affects more males as compared to females
The Eosinophilic Esophagitis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Eosinophilic Esophagitis pipeline products will significantly revolutionize the Eosinophilic Esophagitis market dynamics.
Eosinophilic Esophagitis Overview
Eosinophilic esophagitis is a chronic allergic inflammatory condition that affects the esophagus, the tube that connects the mouth to the stomach. In EoE, the esophagus becomes inflamed due to an allergic reaction to certain foods, environmental allergens, or other triggers. This inflammation leads to the accumulation of eosinophils, a type of white blood cell, in the esophageal tissue, causing symptoms such as difficulty swallowing, chest pain, food impaction, and heartburn.
To Know in detail about the Eosinophilic Esophagitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Eosinophilic Esophagitis Market Forecast
Eosinophilic Esophagitis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Eosinophilic Esophagitis Epidemiology Segmentation:
The Eosinophilic Esophagitis market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:
Total Diagnosed Prevalent Cases of Eosinophilic Esophagitis
Gender-specific Cases of Eosinophilic Esophagitis
Age-specific Cases of Eosinophilic Esophagitis
Treated Cases of Eosinophilic Esophagitis
Download the report to understand which factors are driving Eosinophilic Esophagitis epidemiology trends @ Eosinophilic Esophagitis Epidemiology Forecast
Eosinophilic Esophagitis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Eosinophilic Esophagitis market or expected to get launched during the study period. The analysis covers Eosinophilic Esophagitis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Eosinophilic Esophagitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Eosinophilic Esophagitis Therapies and Key Companies
Dupilumab (DUPIXENT): Sanofi/Regeneron Pharmaceuticals
Budesonide (JORVEZA): Dr. Falk Pharma GmbH
Tezepelumab (TEZSPIRE): AstraZeneca and Amgen
APT-1011 (fluticasone propionate): Ellodi Pharmaceuticals
Kv7 Program: Elium Therapeutics
CG 01: CombiGene
OV329: Ovid Therapeutics
OPC-214870: Otsuka Pharmaceutical Co.,Ltd.
SKL24741: SK Biopharmaceuticals
RLS103: Receptor Life Sciences
CT-010: Cerebral Therapeutics
EQU 001: Equilibre Biopharmaceuticals
Darigabat: Cerevel Therapeutics
ENX-101: Engrail Therapeutics
AMZ002: Amzell
XEN496: Xenon Pharmaceuticals Inc
Discover more about therapies set to grab major Eosinophilic Esophagitis market share @ Eosinophilic Esophagitis Treatment Market
Eosinophilic Esophagitis Market Drivers
Increasing disease awareness and diagnosis: Improved awareness among healthcare professionals and advancements in diagnostic techniques are contributing to higher diagnosis rates of Eosinophilic Esophagitis (EoE).
Growing prevalence of allergic and immune-mediated disorders: The rising incidence of food allergies, asthma, and other atopic conditions is contributing to the growing EoE patient population.
Introduction of novel targeted therapies: The development and approval of biologics and other targeted treatments are expanding therapeutic options and driving market growth.
High unmet medical needs: Limitations associated with conventional treatments and the need for long-term disease management are creating demand for more effective and convenient therapies.
Strong clinical pipeline and ongoing research: Increasing clinical trials and investments in innovative EoE therapies are expected to support future market expansion.
Eosinophilic Esophagitis Market Barriers
Underdiagnosis and delayed diagnosis: EoE symptoms can overlap with other gastrointestinal disorders, leading to misdiagnosis or delays in appropriate treatment.
High treatment costs: The cost of biologics and other advanced therapies may limit patient access and affect market adoption.
Limited long-term treatment data: As EoE is a chronic condition, concerns regarding the long-term safety and efficacy of newer therapies may influence treatment decisions.
Stringent regulatory and reimbursement challenges: Regulatory requirements and variations in reimbursement policies can restrict the uptake of new therapies.
Treatment adherence challenges: Dietary restrictions, repeated endoscopic procedures, and long-term medication use may negatively impact patient compliance.
Scope of the Eosinophilic Esophagitis Market Report
Study Period: 2022–2036
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Eosinophilic Esophagitis Therapeutic Assessment: Eosinophilic Esophagitis current marketed and Eosinophilic Esophagitis emerging therapies
Eosinophilic Esophagitis Market Dynamics: Eosinophilic Esophagitis market drivers and Eosinophilic Esophagitis market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Eosinophilic Esophagitis Unmet Needs, KOL’s views, Analyst’s views, Eosinophilic Esophagitis Market Access and Reimbursement
To know more about Eosinophilic Esophagitis companies working in the treatment market, visit @ Eosinophilic Esophagitis Clinical Trials and Therapeutic Assessment
Table of Contents
1. Eosinophilic Esophagitis Market Report Introduction
2. Executive Summary for Eosinophilic Esophagitis
3. SWOT analysis of Eosinophilic Esophagitis
4. Eosinophilic Esophagitis Patient Share (%) Overview at a Glance
5. Eosinophilic Esophagitis Market Overview at a Glance
6. Eosinophilic Esophagitis Disease Background and Overview
7. Eosinophilic Esophagitis Epidemiology and Patient Population
8. Country-Specific Patient Population of Eosinophilic Esophagitis
9. Eosinophilic Esophagitis Current Treatment and Medical Practices
10. Eosinophilic Esophagitis Unmet Needs
11. Eosinophilic Esophagitis Emerging Therapies
12. Eosinophilic Esophagitis Market Outlook
13. Country-Wise Eosinophilic Esophagitis Market Analysis (2022–2036)
14. Eosinophilic Esophagitis Market Access and Reimbursement of Therapies
15. Eosinophilic Esophagitis Market Drivers
16. Eosinophilic Esophagitis Market Barriers
17. Eosinophilic Esophagitis Appendix
18. Eosinophilic Esophagitis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679 Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
